Coagulation profile of Sudanese children with homozygous sickle cell disease and the effect of treatment with omega-3 fatty acid on the coagulation parameters

BMC Hematology

Research Article

Nazik Elmalaika Husain¹  Mustafa I. Elbashir²  Ahmed A. Daak³  Shiekh Awoda⁴  Kebreab Ghebremeskel⁵ 

[1]College of Medical Laboratory Sciences, Sudan University of Science& Technology, Khartoum, Sudan

[2]Department of Medical Biochemistry, Faculty of Medicine, University of Khartoum, Alghasr Street, Khartoum, Sudan

[3]Department of Medical Biochemistry, Faculty of Medicine, University of Khartoum, Alghasr Street, Khartoum, Sudan

[4]Center of Molecular Biology and Biotechnology (CMBB), Florida Atlantic University (FAU), Boca Raton, USA

[5]Lipidomics and Nutrition Research Centre, London Metropolitan University, London, UK

[6]Department of Medical Biochemistry, Faculty of Medicine, University of Khartoum, Alghasr Street, Khartoum, Sudan

[7]College of Medical Laboratory Sciences, Sudan University of Science& Technology, Khartoum, Sudan

[8]Lipidomics and Nutrition Research Centre, London Metropolitan University, London, UK

关键词: Sickle cell disease;    Coagulation;    Omega-3 fatty acids;    D-dimer;    Protein C;    Protein S;   

DOI  :  10.1186/s12878-017-0089-5

 received in 2017-07-20, accepted in 2017-09-19,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundIt has been reported that patients with SCD do have an abnormal coagulation profile. Coagulopathy is thought to be one of the key factors that contribute to the vaso-occlusive crisis that characterises sickle cell disease (SCD). In this study, we investigated whether Sudanese sickle cell patients have an abnormal coagulation profile. In addition, the effect of treatment with either omega-3 fatty acids or hydroxyurea on coagulation profile was assessed.MethodsHomozygous SCD patients untreated (n = 52), omega-3 treated (n = 44), hydroxyurea (HU) treated (n = 8) and healthy (HbAA) controls (n = 52) matched for age (4–20 years), gender and socioeconomic status were enrolled. Patients on omega-3 fatty acids, according to age, received one to four capsules containing 277.8 mg DHA and 39.0 mg eicosapentnoic. Patients on Hydroxyurea were in on dosage more than 20 mg/kg/day. The steady state levels of the coagulation parameters and the effect of the treatments with either HU or omega-3 fatty acids on markers of coagulation were investigated.ResultsCompared to the healthy controls, treated and untreated HbSS patients had lower hemoglobin, plasma Protein C, proteins S and higher white blood cell count (WBC), platelets count (PLTs) and plasma D-dimer levels,(p < 0.05). In comparison to untreated HbSS, treatment with neither omega-3 nor HU had effect on the WBC, plasma proteins C and S, (p > 0.05). HU treated group had a lower PLTs count compared to HbSS untreated group (p < 0.5). The prothrombin and activated partial thromboplastin times and international normalized ratio (INR) of untreated patients are significantly higher than n-3 treated, HU-treated patients and health controls, (p < 0.05). Patients treated with omega-3 had lowered D-dimer levels in comparison to HU-treated and untreated HbSS patients, (p < 0.001).ConclusionThis study provides evidence that Sudanes patients have abnormal coagulation profile and treatment with either HU or omega-3 fatty acids might partially ameliorate SCD-associated chronic coagulopathic state.

【 授权许可】

CC BY   
© The Author(s). 2017